SI1732565T1 - Peroralni sestavek molsidomina s podaljšanim sproščanjem za zdravljenje ateroskleroze - Google Patents

Peroralni sestavek molsidomina s podaljšanim sproščanjem za zdravljenje ateroskleroze

Info

Publication number
SI1732565T1
SI1732565T1 SI200532067A SI200532067A SI1732565T1 SI 1732565 T1 SI1732565 T1 SI 1732565T1 SI 200532067 A SI200532067 A SI 200532067A SI 200532067 A SI200532067 A SI 200532067A SI 1732565 T1 SI1732565 T1 SI 1732565T1
Authority
SI
Slovenia
Prior art keywords
sustained
composition
release oral
treating atherosclerosis
molsidomine
Prior art date
Application number
SI200532067A
Other languages
English (en)
Inventor
Jozsef-Michel Geczy
Original Assignee
Therabel Pharmaceuticals Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Therabel Pharmaceuticals Limited filed Critical Therabel Pharmaceuticals Limited
Publication of SI1732565T1 publication Critical patent/SI1732565T1/sl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
SI200532067A 2004-04-05 2005-04-01 Peroralni sestavek molsidomina s podaljšanim sproščanjem za zdravljenje ateroskleroze SI1732565T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0403534A FR2868314B1 (fr) 2004-04-05 2004-04-05 Nouvelle utilisation therapeutique de la molsidomine et de ses sels pharmaceutiquement acceptables
EP05755780.3A EP1732565B8 (fr) 2004-04-05 2005-04-01 Composition orale de la molsidomine a liberation prolongee pour le traitement de l"atherosclerose
PCT/EP2005/003531 WO2005107761A1 (fr) 2004-04-05 2005-04-01 Composition orale de la molsidomine a liberation prolongee pour le traitement de l’atherosclerose

Publications (1)

Publication Number Publication Date
SI1732565T1 true SI1732565T1 (sl) 2016-06-30

Family

ID=34944920

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200532067A SI1732565T1 (sl) 2004-04-05 2005-04-01 Peroralni sestavek molsidomina s podaljšanim sproščanjem za zdravljenje ateroskleroze

Country Status (29)

Country Link
US (1) US7754715B2 (sl)
EP (1) EP1732565B8 (sl)
JP (1) JP5117847B2 (sl)
KR (1) KR101162385B1 (sl)
CN (1) CN1938032B (sl)
AU (1) AU2005239799B2 (sl)
BE (1) BE1016580A3 (sl)
BR (1) BRPI0509642A (sl)
CA (1) CA2562287C (sl)
CY (1) CY1117614T1 (sl)
DK (1) DK1732565T3 (sl)
ES (1) ES2567576T3 (sl)
FR (1) FR2868314B1 (sl)
HK (1) HK1092736A1 (sl)
HR (1) HRP20160479T1 (sl)
HU (1) HUE029199T2 (sl)
IL (1) IL178440A0 (sl)
IT (1) ITTO20050220A1 (sl)
MA (1) MA28518B1 (sl)
MD (1) MD4080C1 (sl)
NO (1) NO336913B1 (sl)
NZ (1) NZ550341A (sl)
PL (1) PL1732565T3 (sl)
RS (1) RS54791B1 (sl)
RU (1) RU2388475C2 (sl)
SI (1) SI1732565T1 (sl)
UA (1) UA88461C2 (sl)
WO (1) WO2005107761A1 (sl)
ZA (1) ZA200608219B (sl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2668947T3 (pl) * 2012-05-31 2017-06-30 G. Pohl-Boskamp Gmbh & Co. Kg Indukcja arteriogenezy donorem NO, takim jak nitrogliceryna

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5385937A (en) * 1991-04-10 1995-01-31 Brigham & Women's Hospital Nitrosation of homocysteine as a method for treating homocysteinemia
FR2805462B1 (fr) * 2000-02-24 2003-08-15 Therabel Res Nouvelle forme galenique orale a liberation prolongee de la molsidomine
US6472390B1 (en) * 2001-11-13 2002-10-29 Duke University Use of therapeutic dosages for nitric oxide donors which do not significantly lower blood pressure or pulmonary artery pressure
KR100464876B1 (ko) * 2001-11-15 2005-01-06 학교법인 인제학원 동충하초의 코르디세핀을 함유하는 항혈전제 조성물
WO2010062256A1 (en) * 2008-11-27 2010-06-03 Nanyang Polytechnic Process and system for automatic identification of the larvae of aedes albopictus and aedes aegypti

Also Published As

Publication number Publication date
IL178440A0 (en) 2007-02-11
HK1092736A1 (zh) 2007-02-16
KR20070015534A (ko) 2007-02-05
ES2567576T3 (es) 2016-04-25
EP1732565B1 (fr) 2016-03-09
FR2868314A1 (fr) 2005-10-07
NO336913B1 (no) 2015-11-23
FR2868314B1 (fr) 2008-10-24
BE1016580A3 (fr) 2007-02-06
RU2006134695A (ru) 2008-05-20
UA88461C2 (ru) 2009-10-26
DK1732565T3 (en) 2016-05-09
KR101162385B1 (ko) 2012-07-06
HRP20160479T1 (hr) 2016-06-03
PL1732565T3 (pl) 2016-08-31
US20070212413A1 (en) 2007-09-13
MD4080B1 (en) 2010-12-31
AU2005239799A1 (en) 2005-11-17
HUE029199T2 (en) 2017-03-28
NZ550341A (en) 2009-11-27
RU2388475C2 (ru) 2010-05-10
MA28518B1 (fr) 2007-04-03
CA2562287C (fr) 2013-05-14
JP5117847B2 (ja) 2013-01-16
BRPI0509642A (pt) 2007-09-18
ZA200608219B (en) 2008-02-27
WO2005107761A1 (fr) 2005-11-17
EP1732565A1 (fr) 2006-12-20
CA2562287A1 (fr) 2005-11-17
AU2005239799B2 (en) 2010-12-23
CY1117614T1 (el) 2017-04-26
NO20064510L (no) 2006-10-31
CN1938032A (zh) 2007-03-28
US7754715B2 (en) 2010-07-13
RS54791B1 (sr) 2016-10-31
ITTO20050220A1 (it) 2005-10-06
JP2007531781A (ja) 2007-11-08
MD4080C1 (ro) 2011-07-31
CN1938032B (zh) 2010-06-09
EP1732565B8 (fr) 2016-05-11

Similar Documents

Publication Publication Date Title
EP1744757A4 (en) IMPROVED ENHANCED COMPOSITION
HK1103320A1 (en) Watermark incorporation
EP1710280A4 (en) HARDENING COMPOSITION
GB0409375D0 (en) Phytoactive composition
EP1804787A4 (en) FLAVONOID COMPOSITION FOR THE TREATMENT OF BUCCO-DENTAL DISEASES
EP1726304A4 (en) COMPOSITION CONTAINING SOLIFENACIN
EP1764391A4 (en) POLYOL-NETWORKING FLUORESCENT COMPOSITION
GB0416861D0 (en) Composition
GB0425795D0 (en) Composition
GB0410038D0 (en) Composition
EP1809584A4 (en) composting
IL179357A0 (en) Non infringement composition
EP1967179A4 (en) COMPOSITION FOR ORAL USE
GB0414803D0 (en) Composition
ZA200702581B (en) Composting apparatus
GB0415981D0 (en) Composition
GB0417357D0 (en) Composition
HK1092736A1 (zh) 持續釋放口服嗎多明合成物用於治療動脈粥狀硬化
GB0402738D0 (en) Sullman offset dental luxator
GB0417388D0 (en) Composition
GB0406393D0 (en) Oral composition
GB0406392D0 (en) Oral composition
HK1083195A1 (en) Composition for treating hyperlipidemia
GB0409598D0 (en) Composition
GB0419489D0 (en) Weathered-effect composition